Brief: Acrux Receives FDA Approval For Generic Version Of Aczone® Gel, 5% (Dapsone Gel 5%)
07/06/2023 02:15
June 7 (Reuters) - Acrux Ltd ACR.AX :
* RECEIVES FDA APPROVAL FOR GENERIC VERSION OF ACZONE® GEL,
5%
(DAPSONE GEL 5%)
Source text for Eikon: ID:nASX6NmQ2j
Further company coverage: ACR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share